Covid Alert


Print ISSN:-2394-6784

Online ISSN:-2394-6792

CODEN : IJPOF3

Current Issue

Year 2020

Volume: 7 , Issue: 2

Article Access statistics

Viewed: 311

Emailed: 0

PDF Downloaded: 184

Indian Journal of Pathology and Oncology


Diagnostic utility of Alpha Methylacyl CoA Racemase in prostatic adenocarcinoma: An institutional experience


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Harsha Shrivastava*, S B Patil, Rajashekar KS

Volume : 6, Issue : 3, Year : 2019

Article Page : 368-371


Suggest article by email


Abstract

P504S is a prostate cancer specific gene that encodes for ?-methylacyl CoA racemase (AMACR). AMACR has been shown to be selectively over expressed in prostatic adenocarcinoma with minimal to undetectable expression in benign prostatic tissue. We studied the expression of AMACR in 30 cases of prostatic adenocarcinoma using polyclonal anti-AMACR antibody and correlated it with Gleason score. Extent of staining/proportion score (0: no positive cells; 1+:1-10% positive cells; 2+11-50% positive cells; 3+>50% positive cells) was also recorded and correlated with Gleason score. All the 30 cases showed strong, cytoplasmic granular AMACR staining irrespective of their Gleason score with 26 (86.7%) cases showing immunostaining in more than 50% tumor cells (3+ proportion score). Benign prostate tissue adjacent to adenocarcinoma showed negative AMACR staining. No correlation was seen between Gleason score and AMACR proportion score. We concluded that AMACR is a highly sensitive positive marker of prostatic adenocarcinoma.

Keywords: Prostate adenocarcinoma, Gleason score, AMACR.

Doi : 10.18231/j.ijpo.2019.071

How to cite : Shrivastava H, Patil S B, Rajashekar Ks, Diagnostic utility of Alpha Methylacyl CoA Racemase in prostatic adenocarcinoma: An institutional experience. Indian J Pathol Oncol 2019;6(3):368-371

Copyright © 2019 by author(s) and Indian J Pathol Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)